Loading…
Develops GLP-1 based obesity and metabolic disease drugs licensed from a Chinese biotech partner.
Develops GLP-1 based obesity and metabolic disease drugs licensed from a Chinese biotech partner.
Has no medicine on sale, so it funds studies with money raised from investors. It holds the rights outside China to drugs developed by a Chinese partner, under licence terms that normally include milestone and royalty payments, and would earn from sales only after regulators approve a product.
Moat: narrow (IP / patents, regulatory licence). Backed by major biotech investors with licensed clinical-stage assets in the crowded obesity/GLP-1 race.
Headquarters: Boston, Massachusetts, US · Founded: 2024 · Employees: 145
Size Kailera Therapeutics (KLRA) is a United States Health Care company (Biotechnology) with a market value of $1.68B, the 1911th largest of 3,117 United States companies the cockpit tracks. Shares closed at $12.97 on 6 Nov 2026.
Performance Over six months the shares fell 39.6%, against -5.5% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 18 in its peer set.
Capital Return on invested capital runs 65.4 points below its cost of capital (6.4% WACC).
Short interest Short interest is 6.4% of the free float (15 Oct 2026).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$310,000 | -$53,000 |
| EBITDA | n/a | -$158M | -$16.3M |
| Net income | n/a | -$149M | -$220M |
| Free cash flow | n/a | -$122M | -$124M |
| Capital expenditure | n/a | $2.09M | $262,000 |
| Total debt | $10.2M | $10.8M | $509,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Kailera Therapeutics KLRA | $1.68B | -40% | n/a | n/a | n/a | n/a |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 4.0× | 0.1% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
| Viking Therapeutics VKTX | $3.42B | -17% | n/a | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KLRA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +29.7% | -9.9% | highest of 20 |
| 6-month return | -39.6% | -5.5% | 3rd lowest of 18 |
| Distance from 52-week high | -54.0% | -38.6% | 5th lowest of 20 |
| ROIC minus cost of capital | -65.4 pp | -11.2 pp | 3rd lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |
| Stoke Therapeutics STOK | United States | $1.74B | -19% | -86% | -913% | 50.3× | n/a | n/a |
| Absci ABSI | United States | $1.75B | +72% | -62% | -8,411% | 991.7× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.76B | n/a | -55% | -593% | n/a | n/a | n/a |
| Zhejiang Hengtong 600226.SS | China | $1.76B | -23% | +71% | 0% | 4.5× | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Novavax NVAX | United States | $1.78B | +7% | -62% | -29% | 3.3× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| Mesoblast MSB.AX | Australia | $1.83B | 0% | +556% | -43% | 15.2× | n/a | n/a |